Saturday, October 31, 2026

EUR/JPY Bullish Momentum: 0.91% Up In The Last 5 Sessions

EUR/JPY Bullish Momentum: 0.91% Up In The Last 5 Sessions

(VIANEWS) - EUR/JPY (EURJPY) has been up by 0.91% for the last 5 sessions. At 10:09 EST on Thursday, 20 June, EUR/JPY (EURJPY) is $170.29.

EUR/JPY's yearly highs and lows, it's 15.222% up from its 52-week low and 0.622% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/JPY's Forex is considered to be oversold (<=20).

News about

  • Eur/usd price analysis: holds below 1.0750 ahead of US retail sales data. According to FXStreet on Tuesday, 18 June, "The EUR/USD pair trades on a softer note near 1.0730 on Tuesday during the early European trading hours. ", " According to the 4-hour chart, EUR/USD keeps the bearish vibe unchanged as the major pair holds below the key 100-period Exponential Moving Average (EMA). "
  • According to FXStreet on Wednesday, 19 June, "The EUR/USD pair has continued to stabilize, but still seems to lackenough steam to meaningfully reboundgiven lingering political risk and fiscal concerns weighing on the common currency, ING FX strategists note.", "The eurozone calendar only includes a speech by the European Central Bank'sMarioCenteno today, and we still think the unstable risk environment and downside risks for peripheral bonds will keep EUR/USD capped in the near term."
  • Eur/usd escapes Wednesday’s holiday volatility trap, set for wait to meaningful data. According to FXStreet on Wednesday, 19 June, "The EUR/USD is currently facing resistance from the 200-hour Exponential Moving Average (EMA) at 1.0767, making it challenging for the currency pair to surpass the 1.0750 mark. ", "If this trend continues, the EUR/USD could experience a downside reversal, potentially leading to new lows for 2024, possibly falling below 1.0600."
  • Eur/usd price analysis: seems vulnerable while below 1.0800 confluence support breakpoint. According to FXStreet on Wednesday, 19 June, "The said handle should act as a key pivotal point, which if cleared decisively might prompt a short-covering rally and lift the EUR/USD pair towards the 1.0865-1.0870 supply zone en route to the 1.0900 round-figure mark.", "The EUR/USD pair might then accelerate the fall towards the 1.0650-1.0640 support zone before dropping to the 1.0600 mark, or the YTD low touched in April. "
  • Eur/usd weakens below 1.0750 as eurozone political uncertainty poses downside risks for euro. According to FXStreet on Thursday, 20 June, "The EUR/USD pair weakens near 1.0730, snapping the three-day winning streak during the early European session on Thursday. "

More news about EUR/JPY (EURJPY).

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com